Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOakley Regulatory News (OCI)

Share Price Information for Oakley (OCI)

Share Price is delayed by 15 minutes
Get Live Data
516.00    -4.00 (-0.77%)
Bid:
514.00
Ask:
518.00
Spread: 4.00 (0.778%)
Market Cap: £853.80m
OCI Live PriceLast checked at - London Stock Exchange

Intraday Oakley Share Chart

Trading Statement

24 Jan 2024 07:00

RNS Number : 6857A
Oakley Capital Investments Limited
24 January 2024
Β 

Β 

24 January 2024

Β 

Β 

Β 

Oakley Capital Investments Limited

Β 

Trading update for the year ended 31 December 2023

Β 

Oakley Capital Investments Limited1Β ("OCI" or the "Company") today announces its trading update for the year ended 31 December 2023. OCI is a listed investment company providing consistent, long-term returns in excess of the FTSE All-Share Index by investing in funds managed by Oakley Capital2?("Oakley").Β 

The Oakley Funds3Β invest primarily in unquoted, profitable, pan-European businesses with recurring revenues, and across four focus sectors.Β Oakley's origination capabilities combined with proven value creation drivers help management teams accelerate growth and produce consistently superior returns for investors. ?

Highlights for the year ended 31 December 2023

?

Net Asset Value ("NAV") per share of 684 pence and NAV of Β£1,207 million

?

Total NAV return per share, including dividends, of 4% (+27 pence)

?

Total shareholder return of 18%

?

Investments of Β£175 million and share of proceeds of Β£266 million

?

Year-end cash and available debt of Β£382 million

?

Outstanding commitments of Β£1,017 million

NAV growth

The Company's unaudited NAV as at 31 December 2023 was Β£1,207 million, which represents a NAV per share of 684 pence, based on portfolio valuations at year-end. The total NAV per share return including dividends was 4% (+27 pence) since 31 December 2022 and 1% (+8 pence) since 30 September 2023. Of the realised and unrealised portfolio uplift in the year, 65% of the increase was driven by EBITDA growth, and 35% as a result of multiple expansion. The largest contributions came from IU Group, which expanded enrolments 33% to 125,000 students during the year; North Sails, which generated revenue and profit growth led by the sails, masts and apparel business, ahead of target; and online property portal idealista, which posted strong results across its core markets in Southern Europe.

Portfolio company performance

In 2023, the underlying companies in OCI's portfolio continued to trade well in an uncertain macroeconomic environment, thanks to their resilient, asset-light business models, usually with strong disruptive market positions and predictable, recurring cash flows. Companies across all of Oakley's four sectors, Technology, Consumer, Education and Business Services, contributed to valuation gains.

Proceeds

OCI's look-through share of proceeds from exits and refinancings during the year totalled Β£266 million, consisting of:

?

Realisations - Β£240 million - IU Group exit at gross return of 85% IRR

?

Refinancings - Β£26 million - idealista and Cegid completed debt refinancings

Investments

OCI made a total look-through investment of Β£175 million which included:

?

New platform deals - Β£50 million - Thomas's London Day Schools, Liberty Dental Group and WebCentral

?

Reinvestment - Β£66 million - IU Group, benefitting from the next phase of the company's growth, focused on leveraging AI and internationalisation

?

Follow-on investments - Β£35 million - in addition to vLex's acquisition of Fastcase and 7NXT's acquisition of 7Mind, 22 bolt-on acquisitions were completed by portfolio companies

?

Venture investments - Β£24 million - investments in Oakley Touring Venture Fund and PROfounders III portfolio companies.

Post balance-sheet events

?

Further new platform deals - up to c. Β£100 million - investments in Alerce and Steer Automotive Group. Both transactions are expected to complete within 1H 2024.

Cash & commitments

OCI's total liquidity as at 31 December 2023 was Β£382 million, comprising Β£207 million of cash on the balance sheet and Β£175 million in undrawn credit facilities. OCI made a total commitment of $100 million in Oakley Touring Venture Fund, which focuses on AI-powered software companies, and ?190 million in Origin II, taking the total outstanding commitments to the Oakley Funds to Β£1,017 million as at 31 December 2023. This will be deployed into new investments over the next five years. The Board closely monitors anticipated fund drawdowns and projected liquidity and will continue its long-term commitment to share buybacks when appropriate.

The Company expects to report its audited annual results for 2023 on 14 March 2024.

- ends -

Β 

For further information please contact:

Β 

Oakley Capital Limited

+44 20 7766 6900

Steven Tredget

Β 

Greenbrook Communications Limited

+44 20 7952 2000

Rob White / Michael Russell

Β 

Liberum Capital Limited (Financial Adviser & Broker)

+44 20 3100 2000

Chris Clarke / Darren Vickers / Owen Matthews

Β 

Notes:

LEI Number: 213800KW6MZUK12CQ815

1 About Oakley Capital Investments Limited ("OCI")

OCI is aΒ Specialist Fund Segment ("SFS")Β traded investment vehicle that aims to provide shareholders with consistent long-term capital growth in excess of the FTSE All-Share Index by providing liquid access to private equity returns through investment in the Oakley Funds.

A video introduction to OCI is available atΒ https://oakleycapitalinvestments.com/videos/. The contents of the OCI website are not incorporated into, and do not form part of, this announcement.

2 Oakley Capital, the Investment Adviser

Β 

Founded in 2002, Oakley Capital Limited has demonstrated the repeated ability to source attractive growth assets at attractive prices. To do this it relies on its sector and regional expertise, its ability to tackle transaction complexity and its deal generating entrepreneur network.

3 The Oakley Funds

Oakley Capital Private Equity L.P. and its successor funds, Oakley Capital Private Equity II, Oakley Capital Private Equity III, Oakley Capital IV, Oakley Capital V, Oakley Capital Origin Fund and Oakley Capital Origin II, are unlisted lower-mid to mid-market private equity funds that aim to provide investors with significant long-term capital appreciation. The investment strategy of the Funds is to focus on buy-out opportunities in industries with the potential for growth, consolidation and performance improvement. The Oakley family of funds also includes Oakley PROfounders Fund III and Oakley Touring Venture Fund, which are venture capital funds focused on investments in entrepreneur-led, disruptive, technology led companies.

For more information on the Oakley Fund strategies in which OCI invests, please clickΒ here.

Important information

Specialist Fund Segment securities are not admitted to the Official List of the Financial Conduct Authority. Therefore, the Company has not been required to satisfy the eligibility criteria for admission to listing on the Official List and is not required to comply with the Financial Conduct Authority's Listing Rules.

The Specialist Fund Segment is intended for institutional, professional, professionally advised and knowledgeable investors who understand, or who have been advised of, the potential risk from investing in companies admitted to the Specialist Fund Segment.

This announcement may include "forward-looking statements". These forward-looking statements are statements regarding the Company's objectives, intentions, beliefs or current expectations with respect to, amongst other things, the Company's financial position, business strategy, results of operations, liquidity, prospects and growth. Forward-looking statements are subject to risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. Accordingly the Company's actual future financial results, operational performance and achievements may differ materially from those expressed in, or implied by, the statements. Given these uncertainties, prospective investors are cautioned not to place any undue reliance on such forward-looking statements, which speak only as at the date of this announcement. The Company expressly disclaims any obligation or undertaking to update or revise any forward-looking statements contained herein to reflect actual results or any change in the Company's expectations with regard to them or any change in events, conditions or circumstances on which any such statements are based unless required to do so by the Financial Services and Markets Act 2000, the Listing Rules or Prospectus Regulation Rules of the Financial Conduct Authority or other applicable laws, regulations or rules.

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
TSTDDGDBBDDDGSX
Date   Source Headline
27th Jan 20215:06 pmRNSDirector Dealing
27th Jan 20217:00 amRNSTrading update for the year ended 31 December 2020
26th Jan 20217:00 amRNSInvestment in idealista
7th Jan 20217:00 amRNSSale of the DWS division of the Daisy Group
22nd Dec 20204:11 pmRNSHolding(s) in Company
11th Dec 20202:33 pmRNSDirector Declaration
4th Dec 20203:58 pmRNSHolding(s) in Company
3rd Dec 20204:50 pmEQSHardman & Co Research: Oakley Capital Investments (OCI): NAV: conservative, robust and with growth upside
3rd Dec 20201:52 pmRNSTransaction in Own Shares
25th Nov 20207:00 amRNSHolding(s) in Company
23rd Oct 20207:00 amRNSDirector/PDMR Shareholding
22nd Oct 20207:00 amRNSAcquisition of WindStar Medical
6th Oct 202012:42 pmRNSHolding(s) in Company
6th Oct 20207:00 amRNSTransaction in Own Shares (Amendment)
2nd Oct 20204:33 pmRNSTransaction in Own Shares
2nd Oct 20207:00 amRNSShare Buy-Back Programme
1st Oct 20207:00 amRNSAcquisition of 7NXT
30th Sep 20201:54 pmRNSAppointment of Non-Executive Director
17th Sep 20207:00 amRNSOakley sells Casa.it to EQT
10th Sep 20207:00 amRNSResults for the six months ended 30 June 2020
1st Sep 20207:20 amEQSHardman & Co Research: Oakley Capital Investments (OCI) - initiation of coverage: 'When it rains gold, put out the bucket'
4th Aug 20203:09 pmRNSHolding(s) in Company
29th Jul 20206:15 pmRNSTransaction in Own Shares
29th Jul 20207:00 amRNSTrading update for the six months ended 30 June 20
15th Jul 20209:30 amRNSKepler Trust Intelligence: New Research
6th Jul 20207:00 amRNSCapital Commitment
30th Jun 20207:00 amRNSDirectorate Change
24th Jun 20206:02 pmRNSDirector Dealing
22nd Jun 202012:22 pmRNSHolding(s) in Company
19th Jun 20205:38 pmRNSDirector Dealing
19th Jun 20207:01 amRNSDirector Dealing
19th Jun 20207:00 amRNSDirector Dealing
18th Jun 20205:57 pmRNSHolding(s) in Company
18th Jun 20204:42 pmRNSTransaction in Own Shares
18th Jun 20207:00 amRNSShare Buy-Back
1st Jun 20202:25 pmRNSDirector Declaration
27th May 20205:01 pmRNSHolding(s) in Company
27th May 20207:00 amRNSResult of Annual General Meeting
22nd May 20204:33 pmRNSTime Out equity fundraise and OCI loan repayment
19th May 20207:00 amRNSDirector Declaration
7th May 20207:00 amRNSDirectorate Change and Total Voting Rights
1st May 20207:00 amRNSNotice of Annual General Meeting
8th Apr 20207:00 amRNSOakley completes sale of investment in Inspired
25th Mar 20207:00 amRNSCOVID-19 Update
20th Mar 20207:00 amRNSAnnual Report and Accounts 2019
18th Mar 20204:22 pmRNSTransaction in own Shares
18th Mar 20207:00 amRNSShare Buy-Back
17th Mar 20204:42 pmRNSSecond Price Monitoring Extn
17th Mar 20204:38 pmRNSPrice Monitoring Extension
12th Mar 20207:33 amRNSResults analysis from Kepler Trust Intelligence

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.